Industrial commissioning of AFYREN NEOXY initiated in March, in line with the announced schedule and budget
Net result of - €4.2 million in line with the development plan announced at the IPO (start-up of the first plant in progress and preparation of the next ones)
Securing the sale of 70% of the projected output of organic acids from the AFYREN NEOXY plant thanks to a variety of strategic contracts in all of AFYREN's priority markets
CLERMONT-FERRAND, France & LYON, France, September 27, 2022--(BUSINESS WIRE)--Regulatory News:
AFYREN (Paris:ALAFY), a greentech company that provides manufacturers with bio-based and low-carbon products thanks to its fermentation technology based on a completely circular model, today announced its results for the first half of the current fiscal year, ended June 30, 2022, and approved by the Board of Directors on September 27, 20221.
Nicolas SORDET, CEO of AFYREN declares: "After a year 2021 full of challenges and achievements, this first half-year was the opportunity to pursue and implement our commercial, industrial and CSR strategy. The industrial commissioning of our AFYREN NEOXY plant on the Carling Saint-Avold site was carried out according to the announced schedule and within budget. Over the last few months, we have also built up a diversified portfolio of customers, made up of well-known players in all our target markets. Thanks to these assets and committed to our commitments, we are studying with the highest attention the establishment of a second international plant and confirm our commercial and financial targets. Finally, at the end of a summer during which climate change was top-of-mind worldwide, we are more than ever ideally positioned and committed to helping our customers reduce their impact on the environment."
Key financial information as of June 30, 2022
Change in % of total
Including license and development of industrial know-how
Including other services
Purchases and external expenses
Other expenses and amortization
Net financial income
Share in net income of equity-accounted entities
Sales in H1 2022 increased by 16% to €1.76 million. Sales generated by the licensing agreement amounted to €0.71 million in H1 2022, unchanged from H1 2021. They come exclusively from the lump sum portion of the know-how license granted to AFYREN NEOXY in December 2018. Other services of €1.05 million, up +29% year-on-year, correspond to services invoiced by the Company to AFYREN NEOXY under the agreements signed between the two companies.
Other income amounted to €0.2 million in H1 2022 compared to €0.1 million in H1 2021. They mainly comprise operating subsidies (including in particular the research tax credit) and investment subsidies received.
Current operating expenses amounted to €4.6m compared to €2.5 million on 30 June 2021, an increase of +83% to €2.1 million resulting mainly from the increase in payroll costs (+€1.4 million) and external purchases and expenses (+€0.7 million).
Thus, with the start-up phase of the AFYREN NEOXY plant and the preparation of the next plants, the Company logically recorded a drop in its operating profit as of June 30, 2022, to €-2.58 million.
Net financial expense was €0.2 million in H1 2022, mainly due to interest expenses related to the Company's financial debt and interest related to IFRS restatements.
The share held in the result of AFYREN NEOXY amounts to €-1.4 million on June 30, 2022, against €-0.5 million on June 30, 2021. This evolution is mainly explained by the recruitment of the staff necessary for the operation of the plant.
Finally, the net result is €-4.2 million on June 30, 2022, against €-1.5 million on June 30, 2021. This net loss is in line with the Company's expectations, in a phase where AFYREN and AFYREN NEOXY teams are fully mobilized for the start-up of the first plant and the preparation of the next ones.
Balance sheet as of 30 June 2022
As of June 30, 2022, AFYREN benefits from a solid balance sheet, as its shareholders' equity amounts to €88.9 million, i.e. +159% compared to the first half of 2021 (mainly linked to the capital increase in the framework of the IPO in September 2021) and slightly down by -4.5% compared to December 31, 2021.
Cash and cash equivalents amounted to €64.83 million as of June 30, 2022, mainly including funds raised in connection with AFYREN's IPO in September 2021.
Gross financial debt amounted to €8.6 million as of June 30, 2022, including borrowings and lease liabilities.
As a result, the net cash position was €56.23 million as of June 30, 2022.
H1 2022 Highlights
In line with the announced schedule and budget, the industrial commissioning of the AFYREN NEOXY plant, AFYREN's first large-scale plant, was initiated in March. The industrial unit has since entered the start-up phase, consisting of tests for the gradual commissioning of the various equipment before the actual launch of production.
In May, AFYREN once again demonstrated the relevance of its biosourced, circular and low-carbon offer by signing a strategic contract for the supply of an organic acid from the AFYREN NEOXY range in animal nutrition.
Finally, at the end of May, AFYREN launched new brands for its biobased products in its target markets, offering competitive, high-performance solutions for manufacturers who are increasingly demanding more environmentally friendly alternatives.
Following several months of reflection and consultation, AFYREN has defined and formalized its Purpose: "We enable low-carbon, circular industry by providing biobased solutions built with our partners to benefit the environment". The Company's CSR approach is also supported by a statement defining the Company's ambitions, values, and major commitments, as well as by a new extra-financial rating, up 11 points on the previous year.
The Annual General Meeting of shareholders held on 15 June 2022 approved all of the proposed resolutions, and in particular the appointments to the Board of Directors of Mrs. Patrizia MARRAGHINI as an independent Director and Chairwoman of the Audit Committee and Mrs. Caroline LEBEL as a Director.
Post-closing highlights (30 June 2022)
In July, the Board of Directors authorized the creation of a CSR Committee composed of Ms. Caroline LEBEL, Director, as Chairwoman of the CSR Committee, as well as Ms. Patrizia MARRAGHINI, independent Director, and Mr. Nicolas SORDET, Director and Chief Executive Officer of the company.
In August, AFYREN signed two strategic contracts with players in the cosmetics and nutraceuticals markets. As a result, AFYREN now has signed contracts for its entire portfolio of acids in all of its priority markets. The Company has also pre-sold more than 70% of AFYREN NEOXY’s targeted production volume of organic acids.
Outlook and financial objectives
AFYREN is currently studying the implementation of the plant n°2 for a commissioning at the end of 2024, in particular by the analysis of the various scenarios on several raw materials, in North America and in Asia, by the discussions in progress with potential partners and by the evaluation of the structuring of the financing. These analyses take into account the climate issues and possible opportunities to access an available and low-value raw material through partnership agreements, in order to optimize the carbon impact of the AFYREN solution. These analyses include feasibility studies (in terms of logistics, energy, CO2 impact, security of supply, and customer proximity) which will be used to confirm the deployment schedule.
In the longer term, and with two complementary plants (plant n°2 and n°3), AFYREN reaffirms its outlook and financial objectives:
To have an annual production capacity of more than 70,000 tons by 2026
To reach a positive adjusted current EBITDA margin for AFYREN NEOXY by 2023, and a positive current EBITDA margin for AFYREN by 20252
Achieve a recurring EBITDA margin at Group level of around 30% in 2027 with sales in excess of €150 million3
Availability of the 2022 Half-Year Financial Report
The Company has made available to the public and filed with the Autorité des marchés financiers its 2022 half-year financial report on September 27, 2022.
Founded in 2012 to meet the growing need of industries to reduce the use of petroleum derivatives in their production chain, AFYREN produces biomolecules derived from the reuse of non-food biomass. These ingredients are widely used in human and animal nutrition, flavors and fragrances, cosmetics, and fine chemicals. This production process replicates the exact properties of equivalent petro-sourced molecules, largely used in the human and animal nutrition, cosmetics, flavors and fragrances and fine chemicals sectors.
By offering natural alternatives to these strategic markets, AFYREN is engaged in a low-carbon economy and proposes a truly circular approach with the use of local biomass and the choice of a strategic location, as close as possible to its customers.
Resulting from 10 years of research, AFYREN's disruptive innovation won the 2030 Global Innovation Contest in the "Plant proteins and plant chemistry" category and was selected in the French Tech 120 in 2020 and 2021.
In 2018, AFYREN committed to its industrial project by creating the AFYREN NEOXY joint venture with Bpifrance’s SPI fund. AFYREN NEOXY is dedicated to the first industrial production of AFYREN natural organic acids in the Grand Est region.
In 2022, the AFYREN NEOXY factory opened its doors. AFYREN and AFYREN NEOXY now employ nearly 100 people at their sites in Lyon, Clermont-Ferrand and Carling Saint-Avold.
In 2021, AFYREN listed on Euronext Growth® exchange in Paris with the objective of accelerating its industrial development (Afyren's ISIN: FR0014005AC9, ticker: ALAFY).
For more information: AFYREN.com
INCOME STATEMENT - as of June 30, 2022
Purchases and external expenses
Amortization of capital assets and rights of use
Other expenses and amortization
Net financial result
Share in the result of companies accounted for by the equity method
Profit before tax
Earnings per share
Basic earnings per share (in euros)
Diluted earnings per share (in euros)
BALANCE SHEET - as of June 30, 2022
Property, plant and equipment
Rights of use
Investments in equity affiliates
Non-current financial assets
Current financial assets
Other current assets
Cash and cash equivalents
Net income for the period
Equity attributable to the owners of the Company
Non-current borrowings and financial liabilities
Non-current lease liabilities
Defined benefit liabilities
Non-current deferred income (customer contract liabilities)
Non-current deferred income (grants)
Current borrowings and financial liabilities
Current lease liabilities
Current deferred income (customer contract liabilities)
Other current liabilities
Total equity and liabilities
CASH FLOW STATEMENT - as of 30 June 2022
Net income for the period
Adjustments for :
- Amortization of capital assets and rights of use
- Net financial result
- Share in the result of the company accounted for using the equity method (net of tax)
- Cost of share-based payment
- Income tax
Total eliminations of non-cash expenses and income
Total cash flow
- Trade receivables
- Customer contract liabilities
- Trade payables
- Provisions and employee benefits
- Other current receivables/payables
Cash flow from operating activities
Net cash from operating activities
Acquisition of tangible and intangible assets, excluding development costs
Capitalised development expenses
Investment subsidies (incl. CIR offsetting capitalized costs)
Net cash used in investing activities
Cash receipts from new loans and financial debts
Repayment of loans and financial debts
Payment of rental debts
Interest paid on convertible bonds
Interest paid on loans and financial debts
Interest paid on rental debts
Net cash used in financing activities
Net change in cash and cash equivalents
Cash and cash equivalents at January 1st
Effect of exchange rate changes on cash held
Cash and cash equivalents as of June 30
1 Limited review by the auditor, report in progress
2 Recurring EBITDA is defined at Company level and reflects recurring operating income adjusted for depreciation, amortization and net impairment of property, plant and equipment and intangible assets. Restated current EBITDA is defined at the level of the production units and reflects current operating income adjusted for depreciation, amortization and net impairment of property, plant and equipment and intangible assets, and, where applicable, for the annual flat-rate portion of royalties relating to the remuneration of a technology license granted by Afyren (including the fixed and variable portions).
3 Revenues in excess of €150 million reflect the combined revenues of the production units
View source version on businesswire.com: https://www.businesswire.com/news/home/20220927005841/en/
Théo Martin / Mathilde Bohin
Tél : 01 44 71 94 94
Nicolas Merigeau / Gaëlle Fromaigeat
Tél : 01 44 71 94 98